REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first six months and second quarter

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in Iceland Listing on the Main Market can increase visibility and may allow Alvotech to be included in both Icelandic and international indexes REYKJAVIK,

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to enter clinical studies REYKJAVIK, Iceland , July 20, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO),

Four new members enhance independence and diversity of Board of Directors Alvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” REYKJAVIK, Iceland, July 14, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea ® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion in 2021 The patient study is expected to enroll approximately 444 participants globally

After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland commencing on June 23. Public listing on Nasdaq First North Growth in Iceland offers Icelandic investors